Alaunos Therapeutics
Update in progressTCRT (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Alaunos Therapeutics, Inc. is a clinical-stage company focused on oncology cell therapies. It also develops small-molecule programs for obesity and other metabolic disorders, including an oral obesity compound aimed at improving on injectable GLP-1 therapies by preserving lean muscle mass. The company evaluates ALN1001 and related derivatives for lipid deposition and gene expression, and operates the hunTR TCR discovery platform to target driver mutations. Founded in 2003, based in Houston, Texas.
Company score
- Sentiment
- -0.19
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.13
- Governance
- -0.14
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.07
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.13
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!